Toronto, CANADA, October 20, 2022 — BenchSci, a global leader in machine learning applications for novel medicine development, announced today it released new data to its platform as part of an agreement with Mary Ann Liebert, Inc.
The agreement gives BenchSci’s users access to 100+ biomedical research journals including The CRISPR Journal, Human Gene Therapy, and Journal of Neurotrauma. BenchSci's proprietary AI-powered technology will decode the scientific insights from the data contained in these articles and provide searchable information to users of its platform in order to help them plan, procure reagents for, and execute experiments more effectively.
“Equipping scientists with relevant, timely information makes for more informed decisions and more successful experiments. Yet, new scientific evidence is being published regularly which is why working with publishers like Mary Ann Liebert is vital,” says Eran Ben-Ari, Chief Platform Officer, BenchSci. “By feeding the data from cutting-edge, authoritative journals to our machine learning models, we are able to empower scientists with critical insights so they can do their best work.”
BenchSci’s machine learning technology has been taught to read scientific literature like a Ph.D. scientist. Data from world-leading publications like those at Mary Ann Liebert, Inc. power BenchSci’s Reagent Selection application which users can use to search and filter data from over 30 million experiments and 68 million products—including antibodies, proteins, cells, animal models, PCR, CRISPR, and RNAi. Scientists using BenchSci are able to quickly find critical insights specific to their target of interest and experimental context from the latest in biomedical research. Over 50,000 scientists in academic and pharmaceutical organizations use the platform today.
“We are dedicated to not only publishing the most critical and timely scientific research, but also ensuring that it is readily accessible and discoverable to researchers. This agreement with BenchSci will leverage AI technology to immediately highlight key data from our content, enabling faster and more efficient research processes,” says Bob Vrooman, Director of Business Development at Mary Ann Liebert, Inc.
Access to data from Mary Ann Liebert, Inc. journals will be rolled out to all Reagent Selection users in the upcoming weeks. For more BenchSci updates, visit our News page.
About BenchSci
BenchSci’s vision is to bring novel medicine to patients 50% faster by 2025. We’re achieving it by empowering scientists with the world’s most advanced biomedical artificial intelligence. Backed by top-tier investors including Inovia Capital, TCV, F-Prime, Gradient Ventures (Google’s AI fund), and Golden Ventures, our platform accelerates science at 16 top-20 pharmaceutical companies and over 4,500 leading research centers worldwide. We’re a remote-first Deloitte Tech Fast 50 and CIX Top 10 Growth company, certified Great Place to Work®, and a top-ranked company on Glassdoor. Learn more at www.benchsci.com.
About the Publisher
Mary Ann Liebert, Inc., publishers is a leading independent publisher known worldwide for its prescience and establishment of authoritative peer-reviewed journals, books, and trade publications in cutting-edge fields such as biotechnology and regenerative medicine, biomedical research, medicine and surgery, public health research and policy, technology and engineering, law and policy, environmental research and policy, and other specialized disciplines. The company publishes more than 100 peer-reviewed journals, leading trade magazines, and specialized newsletters which make critical contributions in advancing research and facilitating collaboration throughout the world in academia, industry, and government.
